Metastatic Brain Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metastatic Brain Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Metastatic brain tumors, also known as secondary brain tumors, occur when cancer cells spread to the brain from a primary cancer elsewhere in the body. These tumors are more common than primary brain tumors, arising from cancers originating in other organs such as the lungs, breast, colon, or skin (melanoma) and then migrating to the brain through the bloodstream or lymphatic system.
When cancer cells reach the brain and form tumors, they disrupt normal brain function and can cause a variety of symptoms, including headaches, seizures, nausea or vomiting, changes in vision or hearing, weakness or numbness in the extremities, changes in cognitive abilities or personality, and difficulty with balance or coordination. Diagnosis of metastatic brain tumors typically involves imaging tests such as MRI or CT scans to visualize the tumors and determine their location, size, and number. Biopsies may be performed to confirm the origin of the tumors and guide treatment decisions.
The Metastatic Brain Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Brain Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Brain Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metastatic Brain Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 64 molecules, with 62 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metastatic Brain Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metastatic Brain Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Brain Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ABM Therapeutics IncAccendatech Co Ltd
Affinia Therapeutics
AngioChem Inc
Ashvattha Therapeutics LLC
Aucentra Therapeutics Pty Ltd
Austin Biosciences Corp
Beijing Scitech-MQ Pharmaceuticals Ltd
Beijing zhikangbo Medical Oncology Research Co Ltd
BenevolentAI Ltd
Bioasis Technologies Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
Cantex Pharmaceuticals Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
CNS Pharmaceuticals Inc
Cortice Biosciences Inc
CSPC Pharmaceutical Group Ltd
Divide and Conquer Ltd
Egret Therapeutics Inc
Elucida Oncology Inc
Gan & Lee Pharmaceuticals Co Ltd
Genosco Inc
Genuv Inc
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hebei Senlang Biotechnology Co Ltd
Jubilant Therapeutics Inc
Kadmon Holdings Inc
Kazia Therapeutics Ltd
Komipharm International Co Ltd
Lin Bioscience Inc
Medicenna Therapeutics Corp
Mustang Bio Inc
N1 Life Inc
National Cancer Institute US
Neonc Technologies Inc
NH TherAguix SAS
Novartis AG
Pfizer Inc
Plex Pharmaceuticals Inc
Praesidia Biotherapeutics Inc
Puma Biotechnology Inc
QurCan Therapeutics Inc
Roswell Park Cancer Institute
Shorla Oncology
Sihuan Pharmaceutical Holdings Group Ltd
Smerud Medical Research International AS
SonALASense Inc
Strategia Therapeutics Inc
Suzhou Zanrong Pharmaceutical Technology Co Ltd
Taiho Pharmaceutical Co Ltd
Vacino Biotech Co Ltd
Voyager Therapeutics Inc
Wayshine Biopharma Inc
Zhejiang Yangshengtang Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metastatic Brain Tumor reports